FDA plays 2010/02: RPTP AVNR AOLS

A few stocks to buy at dips for anticipated FDA decision. High risk plays.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP)
Current pps: $2.18
During the first quarter of 2010, Raptor plans to meet with the Food and Drug Administration ("FDA") and European Medicines Agency ("EMEA") to discuss plans for a repeat-dose, pivotal, Phase 3 clinical trial in cystinosis patients. Upon receiving FDA and EMEA agreements on protocol, Raptor intends to initiate its Phase 3 clinical trial at multiple sites in the US and Europe. . . more
http://www.raptorpharma.com/
http://www.google.com/finance?q=rptp

AVANIR Pharmaceuticals (NASDAQ:AVNR)
Current pps: $1.74
AVANIR plans to file a full response to the approvable letter in the second calendar quarter of 2010, with an FDA approval decision expected in the fourth calendar quarter.
Drug: Zenvia for patients suffering from PBA
http://www.avanir.com/
http://www.google.com/finance?q=avnr

Aeolus Pharmaceuticals, Inc. (OTC:AOLS)
Current pps: $0.35
Proposal deadline: February 16, 2010
News jan/12/2010
http://www.aeoluspharma.com/
http://www.google.com/finance?q=aols

*The data provided here may not be current or accurate and has estimated deadlines which can change anytime. Please do your own research before buying any stocks.